Hormone Replacement Therapy on the Postmenopausal Endometrium
NCT ID: NCT02384408
Last Updated: 2015-10-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-11-30
Study Completion Date
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Healthy postmenopausal women, amenorrheic for 1-10 years, aged 45-60 years and in use of follicle stimulating hormone \> 30 mille-International unit/milliliters (mIU/mL), will participate in the study.
All women will be informed by a physician of the risks and possible benefits of Hormone Replacement Therapy (HRT).
The continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg or tibolone 1.25 mg will be administered for a 24-week period.
Transvaginal ultrasound was performed to evaluate the thickness of the endometrium at baseline. At study end-point, an endometrial biopsy will be performed with a Pipelle endometrial sampler to examine histological and immunohistochemical parameters.
Immunohistochemical detection of Bcl-2 protein, estrogen and progesterone receptors will be performed in stroma and glandular epithelium.
All women will be informed by a physician of the risks and possible benefits of Hormone Replacement Therapy (HRT).
The continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg or tibolone 1.25 mg will be administered for a 24-week period.
Transvaginal ultrasound was performed to evaluate the thickness of the endometrium at baseline. At study end-point, an endometrial biopsy will be performed with a Pipelle endometrial sampler to examine histological and immunohistochemical parameters.
Immunohistochemical detection of Bcl-2 protein, estrogen and progesterone receptors will be performed in stroma and glandular epithelium.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Hormone Replacement Therapy on Cardiovascular Risk and Body Composition Parameters
NCT04453332
Menopause
Hormone Replacement Therapy
UNKNOWN
NA
Effects of Tibolone Treatment on the Endometrium
NCT00294463
Postmenopause
Osteoporosis
COMPLETED
PHASE4
Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)
NCT06343870
Menopause
Testosterone Deficiency
Estrogen Deficiency
RECRUITING
PHASE3
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
NCT02337387
Osteoporosis, Postmenopausal
TERMINATED
PHASE1
HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
NCT05280028
Menopausal Syndrome
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects
Healthy postmenopausal women, amenorrheic for 1-10 years, aged 45-60 years and in use of follicle stimulating hormone \> 30 mille-International unit/milliliters (mIU/mL), will participate in the study.
All women will be informed about the trial and signed the informed consent documents, eligibility was determined based on medical history, and on general physical and gynecological examination. All women were informed by a physician of the risks and possible benefits of Hormone Replacement Therapy (HRT). Upon inclusion, Transvaginal ultrasound (TV-US) was performed to evaluate the thickness of the endometrium at baseline. At study end-point, an endometrial biopsy will be performed with a Pipelle endometrial sampler to examine histological and immunohistochemical parameters . Vital signs, blood pressure, weight, Pap smear, mammography, routine clinical chemistry assays (including, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides) and hematology will also be evaluated at screening.
Treatment Groups Of the 100 women initially evaluated, 32 did not meet the inclusion and exclusion criteria, while eight refused to participate, giving a final total of 60 patients for inclusion in the study. The sixty postmenopausal women were randomly allocated into three groups: Group I: control group comprising 20 patients (no hormonal treatment); Group II: also comprising 20 patients, to whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily; and Group III: also comprising 20 patients, to whom treatment with tibolone 1.25 mg (Tib) will be administered daily. All treatments will be administered for a 24-week period. DRSP/E2 was purchased from "Bayer Schering Pharma™", Brazil and Tib from "Biolab™", Brazil. The duration of the treatment will be 6 cycles, each lasting a period of 28 days (conducted for a total of 24 weeks). Randomization will be done with the aid of computer software in order to prevent bias in the selection process.
Objective: A prospective randomized controlled trial will be conducted to evaluate the effect of low dose of tibolone and estradiol/drospirenone on the histology, expression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein, in endometrium of postmenopausal women.
The effects on endometrial thickness will be determined by Transvaginal Ultrasound (TV-USG) at study baseline and again after 6 cycles of treatment in all women participants. Scans were performed with a real-time scanner, "Hitachi 405"ultrasound system equipped with a 5.0-megahertz (MHz) vaginal transducer, at the "Vale do Sapucai University". An endometrial thickness \< 4 millimeters (mm) will be interpreted as not supporting a diagnosis of endometrial cancer.
Endometrial biopsy and sampling will be performed at the end of the treatment course using a "Pipelle Curette" de Cornier, placed high into the upper fundus of the uterus. An aliquot of the endometrial sample will be pushed from the pipette into a polypropylene vial. The vial will be capped, immediately frozen, and then stored at -20º Celsius until shipping in dry ice to the Department of Pathology at the "Vale do Sapucai University", directed by one of the authors, for measurement of Progestogen Receptor (PR) and Estrogen Receptor (ER) receptors as well as Bcl-2 protein. The remaining endometrial tissue will fix in 10% neutral buffered formalin for 6-48 h and then process into paraffin blocks.
Histological and immunohistochemical assessment Histology classification will be carried out by two pathologists. Both pathologists will do a blind reading of different tissue sections of the same block-sample. After staining with hematoxylin/eosin and Schiff Periodic Acid (PAS), each specimen was classified into one of the following categories: tissue insufficient for diagnosis, atrophic and/or inactive endometrium, proliferative or weakly proliferative endometrium, and progestogenic .
Immunohistochemical detection of Bcl-2 protein will be performed by two pathologists. After antigen retrieval and blocking of non-specific sites with normal serum using the Avidin/Biotin Blocking kit (Vector Laboratories, Inc, California, USA), the sections will be incubated overnight at 4º Celsius with anti-Bcl-2 mouse monoclonal antibody (1:100, Clone 124, DAKO, Denmark). The tissue-bound antibody will be incubated for 30 min at room temperature with the Envision System. Staining will be visualized by use of Envision (Kit N1587, DAKO, Denmark). The cellular staining pattern for this antibody is cytoplasmic. The presence of ER and PR will be detected as described previously. The cellular staining patterns for these antibodies are nuclear. A breast cancer specimen will be used as a positive control for the steroid receptors.
Examinations and photography will performed using an "Axioskop 40 - Zeiss" light microscope equipped with a Canon™ D30 digital camera (Tokyo, Japan) and video monitor (LG 14" LCD) according to the procedures of the Pathology Department from Santa Casa of Sao Paulo Medical School, Sao Paulo, Brazil.
The morphometric technique for immunohistochemistry quantification will be done with the aid of a Neubauer graduated chamber. This consists of a glass slide, thicker than a regular slide, each having a grid design dividing it into squares with known dimensions, visualized only through an optical microscope. The Neubauer counting chamber is divided into 9 large squares, each with 1 mm sides, by means of triple lines (thus area of a large square= 1 mm²). Each large square contains 16 (4 x 4) medium-size squares. Each medium size square is further divided by triple lines into 25 (5 x 5) smaller squares, each with a side length of 1/5 of a mm. Thus, the area of an individual small square is 0.05 x 0.05 mm= 0.0025 mm² and 0.1 mm deep .
The image observed through the microscope lenses will be captured by the video camera and displayed on the chosen monitor. The Neubauer chamber will be then placed under the optical microscope, using an objective which magnifies the original size of the object by 400x or by any other magnification elected by the researcher. Finally, the area under the high magnification field (400x magnification) is estimated in mm² by counting the total number of individual small 0.0025 mm² squares of the chamber within the magnification area chosen. The total area under high magnification corresponded to 0.094 mm².
Using this approach, each section prepared by the immunohistochemical method will be evaluated under the light microscope. The number of cells in the study will be counted at 400x magnification. A 10-field count will be performed in the different situations evaluated. The mean number of cells present in this 10-field count represented an area of 0.094 mm². By means of a simple rule of three, the number of cells will be converted into 1 mm² counts. The cell count will be expressed as numerical density, i.e. number of positive cells per square millimeter of epithelium.
The number of Bcl-2-positive cells and immunoreactivity for PR and ER expression will quantified manually by two trained observers, blind to the experiment, and will evaluate separately for glandular and stromal cells. The immunohistochemical staining index (numerical density) will be defined as the mean number of positive immunoexpression cells per mm², calculate in 10 different fields.
Statistical analysis Statistical analysis will be performed using the "StatistiXL Package™" (Statistical Power for Microsoft Excel version 1.8, 2007). Differences in demographic parameters, immunohistochemical staining index of ER, PR and Bcl-2 protein expression (numerical density), as well as baseline and treatment end-point endometrial thickness, will be analyzed by the paired Student's t-test in the different groups. The relationships between ER, PR and Bcl-2 protein expression in stroma and glandular epithelium will be analyzed using Spearman's test.
Statistical significance will set at p \< 0.05. Data will express as mean + standard deviation (SD).
Healthy postmenopausal women, amenorrheic for 1-10 years, aged 45-60 years and in use of follicle stimulating hormone \> 30 mille-International unit/milliliters (mIU/mL), will participate in the study.
All women will be informed about the trial and signed the informed consent documents, eligibility was determined based on medical history, and on general physical and gynecological examination. All women were informed by a physician of the risks and possible benefits of Hormone Replacement Therapy (HRT). Upon inclusion, Transvaginal ultrasound (TV-US) was performed to evaluate the thickness of the endometrium at baseline. At study end-point, an endometrial biopsy will be performed with a Pipelle endometrial sampler to examine histological and immunohistochemical parameters . Vital signs, blood pressure, weight, Pap smear, mammography, routine clinical chemistry assays (including, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides) and hematology will also be evaluated at screening.
Treatment Groups Of the 100 women initially evaluated, 32 did not meet the inclusion and exclusion criteria, while eight refused to participate, giving a final total of 60 patients for inclusion in the study. The sixty postmenopausal women were randomly allocated into three groups: Group I: control group comprising 20 patients (no hormonal treatment); Group II: also comprising 20 patients, to whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily; and Group III: also comprising 20 patients, to whom treatment with tibolone 1.25 mg (Tib) will be administered daily. All treatments will be administered for a 24-week period. DRSP/E2 was purchased from "Bayer Schering Pharma™", Brazil and Tib from "Biolab™", Brazil. The duration of the treatment will be 6 cycles, each lasting a period of 28 days (conducted for a total of 24 weeks). Randomization will be done with the aid of computer software in order to prevent bias in the selection process.
Objective: A prospective randomized controlled trial will be conducted to evaluate the effect of low dose of tibolone and estradiol/drospirenone on the histology, expression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein, in endometrium of postmenopausal women.
The effects on endometrial thickness will be determined by Transvaginal Ultrasound (TV-USG) at study baseline and again after 6 cycles of treatment in all women participants. Scans were performed with a real-time scanner, "Hitachi 405"ultrasound system equipped with a 5.0-megahertz (MHz) vaginal transducer, at the "Vale do Sapucai University". An endometrial thickness \< 4 millimeters (mm) will be interpreted as not supporting a diagnosis of endometrial cancer.
Endometrial biopsy and sampling will be performed at the end of the treatment course using a "Pipelle Curette" de Cornier, placed high into the upper fundus of the uterus. An aliquot of the endometrial sample will be pushed from the pipette into a polypropylene vial. The vial will be capped, immediately frozen, and then stored at -20º Celsius until shipping in dry ice to the Department of Pathology at the "Vale do Sapucai University", directed by one of the authors, for measurement of Progestogen Receptor (PR) and Estrogen Receptor (ER) receptors as well as Bcl-2 protein. The remaining endometrial tissue will fix in 10% neutral buffered formalin for 6-48 h and then process into paraffin blocks.
Histological and immunohistochemical assessment Histology classification will be carried out by two pathologists. Both pathologists will do a blind reading of different tissue sections of the same block-sample. After staining with hematoxylin/eosin and Schiff Periodic Acid (PAS), each specimen was classified into one of the following categories: tissue insufficient for diagnosis, atrophic and/or inactive endometrium, proliferative or weakly proliferative endometrium, and progestogenic .
Immunohistochemical detection of Bcl-2 protein will be performed by two pathologists. After antigen retrieval and blocking of non-specific sites with normal serum using the Avidin/Biotin Blocking kit (Vector Laboratories, Inc, California, USA), the sections will be incubated overnight at 4º Celsius with anti-Bcl-2 mouse monoclonal antibody (1:100, Clone 124, DAKO, Denmark). The tissue-bound antibody will be incubated for 30 min at room temperature with the Envision System. Staining will be visualized by use of Envision (Kit N1587, DAKO, Denmark). The cellular staining pattern for this antibody is cytoplasmic. The presence of ER and PR will be detected as described previously. The cellular staining patterns for these antibodies are nuclear. A breast cancer specimen will be used as a positive control for the steroid receptors.
Examinations and photography will performed using an "Axioskop 40 - Zeiss" light microscope equipped with a Canon™ D30 digital camera (Tokyo, Japan) and video monitor (LG 14" LCD) according to the procedures of the Pathology Department from Santa Casa of Sao Paulo Medical School, Sao Paulo, Brazil.
The morphometric technique for immunohistochemistry quantification will be done with the aid of a Neubauer graduated chamber. This consists of a glass slide, thicker than a regular slide, each having a grid design dividing it into squares with known dimensions, visualized only through an optical microscope. The Neubauer counting chamber is divided into 9 large squares, each with 1 mm sides, by means of triple lines (thus area of a large square= 1 mm²). Each large square contains 16 (4 x 4) medium-size squares. Each medium size square is further divided by triple lines into 25 (5 x 5) smaller squares, each with a side length of 1/5 of a mm. Thus, the area of an individual small square is 0.05 x 0.05 mm= 0.0025 mm² and 0.1 mm deep .
The image observed through the microscope lenses will be captured by the video camera and displayed on the chosen monitor. The Neubauer chamber will be then placed under the optical microscope, using an objective which magnifies the original size of the object by 400x or by any other magnification elected by the researcher. Finally, the area under the high magnification field (400x magnification) is estimated in mm² by counting the total number of individual small 0.0025 mm² squares of the chamber within the magnification area chosen. The total area under high magnification corresponded to 0.094 mm².
Using this approach, each section prepared by the immunohistochemical method will be evaluated under the light microscope. The number of cells in the study will be counted at 400x magnification. A 10-field count will be performed in the different situations evaluated. The mean number of cells present in this 10-field count represented an area of 0.094 mm². By means of a simple rule of three, the number of cells will be converted into 1 mm² counts. The cell count will be expressed as numerical density, i.e. number of positive cells per square millimeter of epithelium.
The number of Bcl-2-positive cells and immunoreactivity for PR and ER expression will quantified manually by two trained observers, blind to the experiment, and will evaluate separately for glandular and stromal cells. The immunohistochemical staining index (numerical density) will be defined as the mean number of positive immunoexpression cells per mm², calculate in 10 different fields.
Statistical analysis Statistical analysis will be performed using the "StatistiXL Package™" (Statistical Power for Microsoft Excel version 1.8, 2007). Differences in demographic parameters, immunohistochemical staining index of ER, PR and Bcl-2 protein expression (numerical density), as well as baseline and treatment end-point endometrial thickness, will be analyzed by the paired Student's t-test in the different groups. The relationships between ER, PR and Bcl-2 protein expression in stroma and glandular epithelium will be analyzed using Spearman's test.
Statistical significance will set at p \< 0.05. Data will express as mean + standard deviation (SD).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Menopause
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Control Group: Women without hormone replacement therapy. Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
Group Type
PLACEBO_COMPARATOR
Endometrial Biopsy
Intervention Type
PROCEDURE
Histological assessment
Transvaginal Ultrasound
Intervention Type
DEVICE
Endometrial Thickness made by ultrasound
Endometrial Immunohistochemical
Intervention Type
PROCEDURE
Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
Hormone treatment
Group Drospirenone: To whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily for 24 weeks.
Group Tibolone: To whom treatment with tibolone 1.25 mg (Tib) will be administered daily for 24 weeks.
Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
Group Type
EXPERIMENTAL
Endometrial Biopsy
Intervention Type
PROCEDURE
Histological assessment
Transvaginal Ultrasound
Intervention Type
DEVICE
Endometrial Thickness made by ultrasound
Endometrial Immunohistochemical
Intervention Type
PROCEDURE
Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endometrial Biopsy
Histological assessment
Intervention Type
PROCEDURE
Transvaginal Ultrasound
Endometrial Thickness made by ultrasound
Intervention Type
DEVICE
Endometrial Immunohistochemical
Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Endometrial Thickness
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy postmenopausal women, amenorrheic for 1-10 years,
* aged 45-60 years and in use of follicle stimulating hormone \> 30 mIU/mL, participated in the study.
* In all subjects, menopausal status will be confirmed by levels of serum follicle stimulating hormone and estradiol in the postmenopausal range.
* an intact uterus,
* a washout period of 8 weeks for oral estrogens with or without progestogens, androgens, or selective estrogen receptor modulators (SERMs), four weeks for transdermal or local sex steroids, and 20 weeks for injections of medroxyprogesterone acetate (MPA) containing contraceptives.
* aged 45-60 years and in use of follicle stimulating hormone \> 30 mIU/mL, participated in the study.
* In all subjects, menopausal status will be confirmed by levels of serum follicle stimulating hormone and estradiol in the postmenopausal range.
* an intact uterus,
* a washout period of 8 weeks for oral estrogens with or without progestogens, androgens, or selective estrogen receptor modulators (SERMs), four weeks for transdermal or local sex steroids, and 20 weeks for injections of medroxyprogesterone acetate (MPA) containing contraceptives.
Exclusion Criteria
* neoplastic, metabolic and infectious diseases,
* a uterine size greater than that consistent with a 12-week gestation,
* any abnormality on bimanual pelvic examination,
* concomitant use of any hormonal drug,
* body mass index (BMI) \> 30 kg/m2,
* cigarette smoking and an endometrial thickness \> 5 mm or the presence of any endometrial abnormalities on transvaginal ultrasound (TV-US).
* No subjects have present or past history of venous thrombosis, cerebrovascular or cardiovascular disease, and
* women were excluded if they had any condition that could alter the pharmacokinetics or hypersensitivity to drospirenone/estradiol and tibolone.
* a uterine size greater than that consistent with a 12-week gestation,
* any abnormality on bimanual pelvic examination,
* concomitant use of any hormonal drug,
* body mass index (BMI) \> 30 kg/m2,
* cigarette smoking and an endometrial thickness \> 5 mm or the presence of any endometrial abnormalities on transvaginal ultrasound (TV-US).
* No subjects have present or past history of venous thrombosis, cerebrovascular or cardiovascular disease, and
* women were excluded if they had any condition that could alter the pharmacokinetics or hypersensitivity to drospirenone/estradiol and tibolone.
Minimum Eligible Age
45 Years
Maximum Eligible Age
60 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Faculdade de Ciências Médicas da Santa Casa de São Paulo
OTHER
Sponsor Role
collaborator
Universidade do Vale do Sapucai
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Benedito Fabiano dos Reis
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benedito F Reis, Prof
Role: PRINCIPAL_INVESTIGATOR
Faculdade de Ciências Médicas da Santa Casa de São Paulo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vale Do Sapucai University (Univas)
Pouso Alegre, Minas Gerais, Brazil
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Brazil
References
Explore related publications, articles, or registry entries linked to this study.
Klaassens AH, van Wijk FH, Hanifi-Moghaddam P, Sijmons B, Ewing PC, Ten Kate-Booij MJ, Kooi GS, Kloosterboer HJ, Blok LJ, Burger CW. Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen. Fertil Steril. 2006 Aug;86(2):352-61. doi: 10.1016/j.fertnstert.2005.12.077. Epub 2006 Jul 7.
Reference Type
RESULT
Lima SM, Reis BF, Yamada SS, Postigo S, Grande RM, Botogoski SR, Campaner AB, Hueb CK, Galvao MA. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. Climacteric. 2011 Oct;14(5):551-7. doi: 10.3109/13697137.2011.559604. Epub 2011 Apr 6.
Reference Type
RESULT
Campaner AB, Longo Galvao MA. Application of an easy and useful morphometric technique for immunohistochemistry counting. Gynecol Oncol. 2009 Jan;112(1):282-3. doi: 10.1016/j.ygyno.2008.08.012. Epub 2008 Oct 19. No abstract available.
Reference Type
RESULT
Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004 Aug 30;48 Suppl 1:S30-40. doi: 10.1016/j.maturitas.2004.02.012.
Reference Type
RESULT
Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304-13. doi: 10.1016/0029-7844(94)00383-O.
Reference Type
RESULT
Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, Brand R, Grady D. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4;280(17):1510-7. doi: 10.1001/jama.280.17.1510.
Reference Type
RESULT
Gokaslan H, Oktem O, Durmusoglu F, Eren F. Apoptosis in the endometrium of postmenopausal women receiving tibolone. Gynecol Obstet Invest. 2003;56(3):124-7. doi: 10.1159/000073624. Epub 2003 Sep 22.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
598.391-0
Identifier Type: OTHER
Identifier Source: secondary_id
10979112.1.3001.5479
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women
NCT00145522
COMPLETED
PHASE4
Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women
NCT01432028
COMPLETED
NA
Efficacy Study of Progesterone Tablet in Post-menopausal Women
NCT02841137
COMPLETED
PHASE2
Bioidentical 'Natural' Hormone Evaluation in Early Menopause
NCT00302731
TERMINATED
PHASE2
TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS
NCT02033512
COMPLETED
PHASE2
Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women
NCT00472004
COMPLETED
PHASE4
Postmenopausal Women Estrogen and Progesterone Infusion
NCT00455741
COMPLETED
PHASE1/PHASE2
Estradiol-Receptor Blockade in Older Men and Women
NCT02271282
COMPLETED
PHASE1
A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
NCT00820664
COMPLETED
PHASE1
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
NCT00808132
COMPLETED
PHASE3
Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)
NCT00413764
COMPLETED
PHASE3
Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
NCT00195546
COMPLETED
PHASE3
Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
NCT00251082
COMPLETED
PHASE3
Thin Endometrium Undergoing Frozen-thawed Embryo Transfer
NCT04292886
UNKNOWN
NA
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
NCT07218445
ACTIVE_NOT_RECRUITING
PHASE4
Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function
NCT03112226
COMPLETED
NA
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
NCT00446199
COMPLETED
PHASE3
A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women
NCT00224094
COMPLETED
PHASE4
Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
NCT00160316
COMPLETED
PHASE3
Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function
NCT01109979
COMPLETED
PHASE4
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
NCT00242710
COMPLETED
PHASE3
Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit
NCT06425978
RECRUITING
PHASE4
Comparison of the Efficacy and Tolerability of Black Cohosh Vs Tibolone in Patients With Menopausal Symptoms
NCT00299364
COMPLETED
PHASE3
A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
NCT01742091
COMPLETED
PHASE1
Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women
NCT02887885
COMPLETED